Lys213

Site Information
sEsLsPVkQAPRksP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4953750

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 )
Disease tissue studied:	lung cancer ( 4 ) , non-small cell lung adenocarcinoma ( 4 ) , multiple myeloma ( 7 , 8 , 9 , 10 , 11 , 12 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 4 ) , HEp-2 (squamous) ( 1 ) , JJN3 (plasma cell) ( 11 , 12 , 19 , 20 , 23 , 24 , 25 ) , LNCaP (prostate cell) ( 34 , 35 , 36 , 37 , 38 , 39 ) , MKN-45 (gastric) ( 41 , 42 ) , NT2 (testicular) ( 13 ) , PC3 (prostate cell) ( 31 , 32 , 33 ) , RPMI-8266 (plasma cell) ( 9 , 10 , 14 , 15 , 16 , 17 , 18 ) , U266 (plasma cell) ( 7 , 8 , 21 , 22 , 26 , 40 ) , U2OS (bone cell) ( 5 )

Upstream Regulation
Treatments:	vorinostat ( 4 )

References
1	Akimov V, et al. (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25, 631-640 29967540 Curated Info
2	Lumpkin RJ, et al. (2017) Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. Nat Commun 8, 1171 29079793 Curated Info
3	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
4	Wu Q, et al. (2015) Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line. Sci Rep 5, 9520 25825284 Curated Info
5	Povlsen LK, et al. (2012) Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. Nat Cell Biol 14, 1089-98 23000965 Curated Info
6	Kim W, et al. (2011) Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44, 325-40 21906983 Curated Info
7	Guo A (2010) CST Curation Set: 10264; Year: 2010; Biosample/Treatment: cell line, U266/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
8	Guo A (2010) CST Curation Set: 10265; Year: 2010; Biosample/Treatment: cell line, U266/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
9	Guo A (2010) CST Curation Set: 10262; Year: 2010; Biosample/Treatment: cell line, RPMI-8266/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
10	Guo A (2010) CST Curation Set: 10263; Year: 2010; Biosample/Treatment: cell line, RPMI-8266/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
11	Beausoleil S (2010) CST Curation Set: 9659; Year: 2010; Biosample/Treatment: cell line, JJN3/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
12	Beausoleil S (2010) CST Curation Set: 9660; Year: 2010; Biosample/Treatment: cell line, JJN3/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
13	Zhou J (2010) CST Curation Set: 9132; Year: 2010; Biosample/Treatment: cell line, NTERA-2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
14	Guo A (2009) CST Curation Set: 8668; Year: 2009; Biosample/Treatment: cell line, RPMI-8266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
15	Guo A (2009) CST Curation Set: 8669; Year: 2009; Biosample/Treatment: cell line, RPMI-8266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
16	Guo A (2009) CST Curation Set: 8667; Year: 2009; Biosample/Treatment: cell line, RPMI-8266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
17	Guo A (2009) CST Curation Set: 8670; Year: 2009; Biosample/Treatment: cell line, RPMI-8266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
18	Guo A (2009) CST Curation Set: 8666; Year: 2009; Biosample/Treatment: cell line, RPMI-8266/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
19	Guo A (2009) CST Curation Set: 8650; Year: 2009; Biosample/Treatment: cell line, JJN3/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
20	Guo A (2009) CST Curation Set: 8649; Year: 2009; Biosample/Treatment: cell line, JJN3/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
21	Guo A (2009) CST Curation Set: 8643; Year: 2009; Biosample/Treatment: cell line, U266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
22	Guo A (2009) CST Curation Set: 8642; Year: 2009; Biosample/Treatment: cell line, U266/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
23	Guo A (2009) CST Curation Set: 8651; Year: 2009; Biosample/Treatment: cell line, JJN3/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
24	Guo A (2009) CST Curation Set: 8648; Year: 2009; Biosample/Treatment: cell line, JJN3/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
25	Guo A (2009) CST Curation Set: 8652; Year: 2009; Biosample/Treatment: cell line, JJN3/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
26	Guo A (2009) CST Curation Set: 8644; Year: 2009; Biosample/Treatment: cell line, U266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
27	Guo A (2009) CST Curation Set: 8639; Year: 2009; Biosample/Treatment: cell line, L363/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
28	Guo A (2009) CST Curation Set: 8635; Year: 2009; Biosample/Treatment: cell line, L363/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
29	Guo A (2009) CST Curation Set: 8637; Year: 2009; Biosample/Treatment: cell line, L363/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
30	Guo A (2009) CST Curation Set: 8640; Year: 2009; Biosample/Treatment: cell line, L363/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
31	Possemato A (2009) CST Curation Set: 8585; Year: 2010; Biosample/Treatment: cell line, PC3/Geldanamycin; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
32	Possemato A (2009) CST Curation Set: 8581; Year: 2010; Biosample/Treatment: cell line, PC3/control; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
33	Possemato A (2009) CST Curation Set: 8582; Year: 2010; Biosample/Treatment: cell line, PC3/AAG; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
34	Possemato A (2009) CST Curation Set: 8244; Year: 2010; Biosample/Treatment: cell line, LNCaP/Geldanamycin; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
35	Possemato A (2009) CST Curation Set: 8247; Year: 2010; Biosample/Treatment: cell line, LNCaP/Velcade; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
36	Possemato A (2009) CST Curation Set: 8242; Year: 2010; Biosample/Treatment: cell line, LNCaP/AAG; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
37	Possemato A (2009) CST Curation Set: 8246; Year: 2010; Biosample/Treatment: cell line, LNCaP/Velcade; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
38	Possemato A (2009) CST Curation Set: 8245; Year: 2010; Biosample/Treatment: cell line, LNCaP/Geldanamycin; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
39	Possemato A (2009) CST Curation Set: 8241; Year: 2010; Biosample/Treatment: cell line, LNCaP/control; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
40	Possemato A (2009) CST Curation Set: 6586; Year: 2009; Biosample/Treatment: cell line, U266/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
41	Guo A (2008) CST Curation Set: 5566; Year: 2008; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
42	Guo A (2008) CST Curation Set: 5567; Year: 2008; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info